Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Agarwal, Ekta ^a   Chaudhuri, Anathbandhu ^b   Leiphrakpam, Premila D ^a   Haferbier, Katie L ^a   Brattain, Michael G ^a   Chowdhury, Sanjib ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b STILLMAN COLLEGE   (United States)

Author keywords

AIF; Akt inhibitor MK 2206; Akt isoforms; Cell death; Cell survival; Ezrin T567; PI3K; Survivin; XIAP

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; APOPTOSIS INDUCING FACTOR; CASPASE; EZRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CYTOSKELETON PROTEIN; FUSED HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG CYTOTOXICITY; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895100568     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-145     Document Type: Article

References (44)

1. Shtilbans V, Wu M, Burstein DE. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 2008, 12(2):153-160. 10.1016/j.anndiagpath.2007.12.001, 18325479.
2. Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jucker M. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal 2011, 23(12):1952-1960. 10.1016/j.cellsig.2011.07.003, 21777670.
3. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2011, 346:31-56.
4. Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 2013, 25(8):1711-1719. 10.1016/j.cellsig.2013.03.025, 23603750.
5. Janes SM, Watt FM. Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis. J Cell Biol 2004, 166(3):419-431. 10.1083/jcb.200312074, 2172256, 15289499.
6. Zhan M, Zhao H, Han ZC. Signalling mechanisms of anoikis. Histol Histopathol 2004, 19(3):973-983.
7. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14(5):381-395. 10.1016/S0898-6568(01)00271-6, 11882383.
8. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003, 63(9):2172-2178.
9. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24(50):7443-7454. 10.1038/sj.onc.1209091, 16288291.
10. Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, Weber HR, Chowdhury A, Brattain MG. Identification of a novel TGFbeta/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One 2011, 6(5):e19335. 10.1371/journal.pone.0019335, 3086924, 21559296.
11. Chowdhury S, Howell GM, Teggart CA, Chowdhury A, Person JJ, Bowers DM, Brattain MG. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem 2011, 286(35):30937-30948. 10.1074/jbc.M110.212035, 3162453, 21757750.
12. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao J, Keihack H, Yan L, Rubin E, Yang JM. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012, 11(1):154-164. 10.1158/1535-7163.MCT-11-0606, 3302182, 22057914.
13. Lai YC, Liu Y, Jacobs R, Rider MH. A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle. Biochem J 2012, 447(1):137-147. 10.1042/BJ20120772, 22793019.
14. Liu R, Liu D, Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab 2012, 97(2):E173-182. 10.1210/jc.2011-1054, 3275354, 22090271.
15. Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008, 68(19):8004-8013. 10.1158/0008-5472.CAN-08-0280, 18829558.
16. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 2000, 476(3):118-123. 10.1016/S0014-5793(00)01731-2, 10913597.
17. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 2007, 109(12):5455-5462. 10.1182/blood-2006-12-063958, 17317853.
18. Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X, Liao J, Ward T, Xia P, Emenari C, Ding X, Thompson W, Ma K, Zhu J, Aikhionbare F, Dou K, Cheng SY, Yao X. Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res 2011, 71(5):1721-1729. 10.1158/0008-5472.CAN-09-4683, 3119000, 21363921.
19. Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, Liu P, Song A, Gang C, Han Z, Zhou J, Meng L, Lu Y, Wang S, Ma D. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008, 261(1):55-63. 10.1016/j.canlet.2007.11.018, 18155831.
20. Nakabayashi H, Shimizu K. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 2011, 102(2):393-399. 10.1111/j.1349-7006.2010.01794.x, 21166955.
21. Wu KL, Khan S, Lakhe-Reddy S, Jarad G, Mukherjee A, Obejero-Paz CA, Konieczkowski M, Sedor JR, Schelling JR. The NHE1 Na+/H + exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival. J Biol Chem 2004, 279(25):26280-26286. 10.1074/jbc.M400814200, 15096511.
22. Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996, 271(29):17366-17371. 10.1074/jbc.271.29.17366, 8663343.
23. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res 1999, 59(18):4725-4731.
24. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 2008, 68(9):3152-3160. 10.1158/0008-5472.CAN-07-5348, 18451140.
25. Mulder KM, Brattain MG. Effects of growth stimulatory factors on mitogenicity and c-myc expression in poorly differentiated and well differentiated human colon carcinoma cells. Mol Endocrinol 1989, 3(8):1215-1222. 10.1210/mend-3-8-1215, 2674694.
26. Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM. Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 2002, 21(18):2785-2796. 10.1038/sj.onc.1205375, 11973637.
27. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001, 20(57):8203-8214. 10.1038/sj.onc.1205044, 11781836.
28. Ongchin M, Sharratt E, Dominguez I, Simms N, Wang J, Cheney R, LeVea C, Brattain M, Rajput A. The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancer. J Surg Res 2009, 156(2):250-256. 10.1016/j.jss.2009.02.002, 19524264.
29. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91(2):231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
30. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW, Dawson TM, Dawson VL, Park DS, Kroemer G, Slack RS. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002, 158(3):507-517. 10.1083/jcb.200202130, 2173837, 12147675.
31. Shiue H, Musch MW, Wang Y, Chang EB, Turner JR. Akt2 phosphorylates ezrin to trigger NHE3 translocation and activation. J Biol Chem 2005, 280(2):1688-1695. 1237052, 15531580.
32. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2011, 59(3):518-524. 3290691, 22102563.
33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26(11):2336-2342. 10.1038/leu.2012.136, 22614243.
34. Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Tsao SW, Li Y, Chan AT. Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Invest New Drugs 2013, 31(3):567-75. 10.1007/s10637-012-9896-5, 23143779.
35. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996, 84(6):889-897. 10.1016/S0092-8674(00)81067-3, 8601312.
36. Yang X, Fraser M, Abedini MR, Bai T, Tsang BK. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer 2008, 98(4):803-808. 10.1038/sj.bjc.6604223, 2259169, 18283299.
37. Cheung EC, Melanson-Drapeau L, Cregan SP, Vanderluit JL, Ferguson KL, McIntosh WC, Park DS, Bennett SA, Slack RS. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J Neurosci 2005, 25(6):1324-1334. 10.1523/JNEUROSCI.4261-04.2005, 15703386.
38. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397(6718):441-446. 10.1038/17135, 9989411.
39. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell 2010, 17(1):53-64. 10.1016/j.ccr.2009.11.021, 2818597, 20129247.
40. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007, 27(1):17-28. 10.1016/j.molcel.2007.06.004, 1986705, 17612487.
41. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, Cheng JQ. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004, 279(7):5405-5412.
42. Turunen O, Wahlstrom T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 1994, 126(6):1445-1453. 10.1083/jcb.126.6.1445, 2290954, 8089177.
43. Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, Arpin M. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 2004, 164(5):653-659. 10.1083/jcb.200307032, 2172172, 14993232.
44. Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, Arpin M, Gschmeissner S, Verveer PJ, Bastiaens PI, Parker PJ. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J 2001, 20(11):2723-2741. 10.1093/emboj/20.11.2723, 125254, 11387207.